Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

A new study found that, among nearly 775,000 pregnant people in Massachusetts, 31 percent of these individuals had at least one unscheduled emergency visit to the hospital, and 3.3 percent had four or ...